Eldelumab

Uses your system voice; voice and rate in settings.

Q10423561Snapshot

≈ 1 min read

Names in other languages

  • العربيةإلديلوماب
  • EnglishEldelumab
  • ItalianoEldelumab
  • فارسیالدلوماب
  • 中文埃迪鲁单抗

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Eldelumab (alternative identifier BMS-936557 ) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis. This drug was developed by Bristol-Myers Squibb and Medarex.

Eldelumab (alternative identifier BMS-936557 ) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis. This drug was developed by Bristol-Myers Squibb and Medarex.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1187917134 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.